Atopic dermatitis (AD) affects approximately 10% of the canine population globally and is likely the most prevalent skin disease in the dog requiring medical intervention. Current treatment options for canines include antihistamines, corticosteroids, cyclosporine A, oclacitinib, and allergen-specific immunotherapy (ASIT) administered subcutaneously or sublingually, as well as adjunctive treatments such as topical and systemic antimicrobial therapy. Avoidance of implicated allergens is impractical or impossible in most cases. The problem with the above treatment options is that they are not entirely reliable therapeutic modalities, have the potential for adverse reactions, or they come with significant financial burden. There is a great need for finding a novel, safe, and effective treatment for the management of canine AD.
Multipotent mesenchymal stem cells (MSCs) have been extensively evaluated in human medicine for their clinical applications in the repair of damaged tissues and in the treatment of chronic, degenerative inflammatory diseases because of their diverse wound healing and anti-inflammatory properties.
Our primary goal is to investigate the efficacy of autologous Bone Marrow MSCs (BM-MSCs) in alleviating the clinical signs associated with canine AD and the safety of BM-MSCs given that no prior safety study has been performed at our hospital. Our secondary goal is to investigate the feasibility of this protocol for future applications in larger scale randomized controlled double-blinded clinical trials.
For more information regarding this study, please visit: http://sites.tufts.edu/vetclinicaltrials/specialty/dermatology/